Oncology
The clinical research activity of Ona Therapeutics S.L. is centered on advanced cancer, with particular attention to breast cancer and metastatic gastric and gastroesophageal junction cancer.
- Advanced cancer
- Breast cancer
- Metastatic gastric cancer
- Gastroesophageal junction cancer
Its funded research reflects a focus on difficult-to-treat solid tumours, including HR+/HER2- advanced breast cancer and metastatic gastroesophageal malignancies.
Solid Tumour Therapeutics
Research supported by the company is directed toward treatment development in solid tumours, with emphasis on patients whose disease has progressed to an advanced or metastatic stage.
- Metastatic disease
- Hormone receptor-positive breast cancer
- HER2-negative breast cancer
- Gastric and gastroesophageal junction tumours
The therapeutic scope includes indications where tumour burden and treatment resistance are major clinical concerns.
Early Clinical Development
The sponsor’s trial portfolio includes work in early-stage clinical investigation aimed at defining the biological and therapeutic activity of ONA-255 across selected cancer populations.
- Biological activity assessment
- Dose optimisation
- Safety and efficacy evaluation
- Response assessment
This area of interest spans single-agent oncology treatment in both breast and gastrointestinal cancer settings.
Targeted Cancer Treatment
The research landscape indicates an interest in targeted therapeutic approaches for patients with advanced solid tumours, especially in settings where standard options are limited.
- Targeted oncology agents
- Advanced breast cancer treatment
- Gastric cancer treatment
- Gastroesophageal junction cancer treatment
Clinical interest is concentrated in tumour types with significant unmet therapeutic need and poor prognosis.
